Biolegend, 309809, APC anti-human CD137 (4-1BB) Antibody, 25tests

CD137 is a 39 kD transmembrane protein also known as 4-1BB. It is expressed on activated T cells. CD137 is a type I membrane protein and a member of the tumor necrosis factor receptor superfamily. CD137 appears to be important for T cell proliferation and survival, and induces monocyte activation through its interaction with 4-1BB ligand.
25tests
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Ectodomain of recombinant human 4-1BB fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation1,4, inhibition of cytokine production2,3, and ELISA. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 309804) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-mouse IgG second step (Cat. No. 405303), followed by Streptavidin-PE (Cat. No. 405204)).
Application References(PubMed link indicates BioLegend citation): Garni-Wagner B, et al. 1996. Cell. Immunol. 169:91. (IP) Salih HR, et al. 2000. J. Immunol. 165:2903. (FA) Kienzle G, et al. 2000. Int. Immunol. 12:73. (FA) Langstein J, et al. 1998. J. Immunol. 160:2488. (IP)
Product Citations: Tarke A, et al. 2021. Cell Reports Medicine. 2(2):100204. PubMed Terahara K, et al. 2022. iScience. 25:104959. PubMed Sun P, et al. 2022. iScience. 25:105202. PubMed Fendler A, et al. 2022. Cell Rep Med. 3:100781. PubMed Ryan FJ, et al. 2023. Cell Rep Med. 4:100971. PubMed Nguyen THO, et al. 2023. Cell Rep Med. 4:101017. PubMed Xiao C, et al. 2023. Nat Aging. 3:418. PubMed Zhang W, et al. 2023. Nat Immunol. 24:966. PubMed Tarke A, et al. 2023. Cell Rep Med. 4:101088. PubMed Apostolidis SA, et al. 2021. Nat Med. 27:1990. PubMed Nielsen MA, et al. 2022. Front Immunol. 13:915890. PubMed Hong CH, et al. 2022. Front Immunol. 13:1021067. PubMed Yu ED, et al. 2022. Cell Rep Methods. 2:100350. PubMed Eschweiler S 2023. Cell Reports. 42(2):112040. PubMed Luo X, et al. 2020. Front Immunol. 11:623. PubMed Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed Stevenson EM, et al. 2022. Nat Commun. 13:4888. PubMed Grifoni A, et al. 2020. J Virol. 94:00:00. PubMed van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed Yarmarkovich M, et al. 2021. Nature. 599:477. PubMed Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed Tarke A, et al. 2021. Cell Reports Medicine. 2(7):100355. PubMed You M, et al. 2021. Nat Cell Biol. 23:620. PubMed Painter MM, et al. 2021. Immunity. 54:2133. PubMed Zhang J, et al. 2022. Nature. 609:369. PubMed Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed Grifoni A, et al. 2020. Cell. 181(7):1489-1501.e15.. PubMed Tarke A, et al. 2022. Cell. 185:847. PubMed Valenzuela NM, et al. 2021. Front Immunol. 12:648946. PubMed Voic H, et al. 2020. J Virol. 94: . PubMed Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed Kishton RJ, et al. 2022. Cell Rep. 40:111153. PubMed Yu ED, et al. 2022. Cell Host Microbe. 30:1269. PubMed Mo F, et al. 2021. Nat Biotechnol. 56:39. PubMed Martin SD, et al. 2018. Oncoimmunology. 7:e1371895. PubMed Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed Tarke A, et al. 2022. Int J Mol Sci. 23:. PubMed Motozono C, et al. 2021. Cell Host Microbe. . PubMed Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed Lederer K, et al. 2022. Cell. . PubMed Schouest B, et al. 2021. J Virol. 95:. PubMed Eriksen LL, et al. 2021. PLoS One. 16:e0255574. PubMed Reitinger C, et al. 2022. Front Immunol. 13:970290. PubMed Nuffel A, et al. 2012. J Immunol Methods. 377:23. PubMed Yu ED, et al. 2022. Cell Host Microbe. . PubMed Nesterenko PA, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
RRID: AB_830671 (BioLegend Cat. No. 309809) AB_830672 (BioLegend Cat. No. 309810)
Structure: TNFR superfamily, type I transmembrane protein, 30 kD
Distribution: Activated T cells
Function: T cell costimulation
Ligand/Receptor: 4-1BB ligand
Cell Type: T cells
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Gruss H, et al. 1995. Blood 85:3378. 2. Sica G, et al. 2000. Adv. Exp. Med. Biol. 465:355. 3. Alderson M, et al. 1994. Eur. J. Immunol. 24:2219. 4. Schwarz H, et al. 1996. Blood 87:2839.
Gene ID: 3604
UniProt: View information about CD137 on UniProt.org
Clone: 4B4-1
Regulatory Status: RUO
Workshop: VI C-7
Other Names: 4-1BB, ILA, CD137, TNFRSF9
Isotype: Mouse IgG1, κ